Skip to main content English

Detail

Martin Riesenhuber
Dr.med.univ. Martin Riesenhuber

Department of Medicine II (Division of Cardiology)
Position: PHD Student

ORCID: 0000-0002-5061-7354
T +43 1 40400 - 46140
martin.riesenhuber@meduniwien.ac.at

Keywords

Animal Experimentation; Arrhythmias, Cardiac; Cardiac Catheterization; Cardiac Electrophysiology; Cardiac Imaging Techniques; Cardiac Pacing, Artificial; Cardiac Resynchronization Therapy; Cardiovascular Diseases; Coronary Artery Disease; Myocardial Ischemia

Research group(s)

Research interests

Martin Riesenhuber is a medical doctor focused on clinical cardiology and cardiovascular research with broad experience in cardiac device therapy, electrophysiology and large animal models, including diagnostic and interventional coronary angiography, cardiac imaging, device and drug testing and translational studies for cardiac remodeling in pigs. He is part of the consortium of CResPace EU-project, developing a new generation of CRT devices, adapting beat-to-beat to the individual needs of patients.

During the diploma program medicine at the Medical University of Vienna (completed in 2017) he received two merit-based scholarships, gained experience in preclinical intensive care medicine and analyzed up to 1,300 24h-ECGs. He did 8 months of clinical training in Switzerland.

Working within the research group of Univ. Prof. Dr. Pavone-Gyöngyösi since 2015, he is a PhD candidate since 2017.

Techniques, methods & infrastructure

  • Coronary angiography in pigs (creation of 190 reperfused myocardial infarcts and 165 diagnostic angiographies in pigs from 09/2017 to 07/2018)
  • Cardiovascular Imaging including cardiac MRI
  • Cardiac Drug Testing
  • Cardiac Device Testing
  • Broad experience in Pressure-Volume loops of the left ventricle

Selected publications

  1. Riesenhuber, M. et al. (2021) ‘Pacemaker lead-associated tricuspid regurgitation in patients with or without pre-existing right ventricular dilatation’, Clinical Research in Cardiology, 110(6), pp. 884–894. Available at: http://dx.doi.org/10.1007/s00392-021-01812-3.
  2. Riesenhuber, M. et al. (2020) ‘Sex Differences and Long-Term Outcome in Patients With Pacemakers’, Frontiers in Cardiovascular Medicine, 7. Available at: http://dx.doi.org/10.3389/fcvm.2020.569060.
  3. Batkai, S. et al. (2020) ‘CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure’, European Heart Journal, 42(2), pp. 192–201. Available at: http://dx.doi.org/10.1093/eurheartj/ehaa791.
  4. Foinquinos, A. et al. (2020) ‘Preclinical development of a miR-132 inhibitor for heart failure treatment’, Nature Communications, 11(1). Available at: http://dx.doi.org/10.1038/s41467-020-14349-2.
  5. Spannbauer, A. et al. (2019) ‘Effect of Ischemic Preconditioning and Postconditioning on Exosome-Rich Fraction microRNA Levels, in Relation with Electrophysiological Parameters and Ventricular Arrhythmia in Experimental Closed-Chest Reperfused Myocardial Infarction’, International Journal of Molecular Sciences, 20(9), p. 2140. Available at: http://dx.doi.org/10.3390/ijms20092140.